Xencor (NASDAQ:XNCR) Issues Earnings Results

Xencor (NASDAQ:XNCR) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.83, FiscalAI reports. The firm had revenue of $116.52 million for the quarter, compared to analysts’ expectations of $63.00 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%.

Xencor Trading Up 14.3%

XNCR traded up $4.39 during trading on Wednesday, reaching $35.03. The stock had a trading volume of 2,536,875 shares, compared to its average volume of 1,054,930. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -16.14 and a beta of 0.78. The stock’s 50 day moving average is $25.81 and its two-hundred day moving average is $17.13. Xencor has a one year low of $10.38 and a one year high of $35.05.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on XNCR shares. Royal Bank Of Canada boosted their price target on Xencor from $20.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, October 27th. Truist Financial increased their price objective on Xencor from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Cantor Fitzgerald lifted their price objective on Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, September 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.